Meeting
2016 Gastrointestinal Cancers Symposium
The ATOM trial: A multicenter, randomized phase II study of modified FOLFOX6 plus bevacizumab and modified FOLFOX6 plus cetuximab for colorectal cancer with liver-limited metastases.
Authors
Yasunori Emi
Department of Surgery, Saiseikai Fukuoka General Hospital, Fukuoka, Japan
Yasunori Emi , Kei Muro , Takeharu Yamanaka , Yu Katayose , Hiroyuki Uetake , Kenichi Sugihara , Yoshihiro Kakeji , Michiaki Unno , Ichinosuke Hyodo , Naohiro Tomita , Yoshihiko Maehara
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01836653
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr TPS777)
DOI
10.1200/jco.2016.34.4_suppl.tps777
Abstract #
TPS777
Poster Bd #
O8
Abstract Disclosures
Similar Posters
Poster
2015 Gastrointestinal Cancers Symposium
Randomized phase II studies comparing pathological responses observed on colorectal cancer metastases resected after preoperative treatment combining bevacizumab or cetuximab with FOLFOX or FOLFIRI.
First Author: Marc Van Den Eynde
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Preoperative chemotherapy prior to primary tumor resection for asymptomatic synchronous unresectable colorectal liver-limited metastases: A multicenter randomized controlled trial.
First Author: Qi Lin
Poster
2019 ASCO Annual Meeting
Randomized phase II study on the influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab (Bev) or cetuximab (Cet), as first line therapy of patients (pts) with RAS wild-type metastatic colorectal carcinoma (mCRC) and <3 baseline circulating tumor cells (bCTCs).
First Author: Enrique Aranda
Poster
2018 Gastrointestinal Cancers Symposium
A randomized phase II study of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab for previously untreated, liver-limited metastatic colorectal cancer that is unsuitable for resection (ATOM trial).
First Author: Hiroyuki Uetake